Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.59 USD | -3.72% | -2.26% | -7.83% |
May. 14 | Transcript : IRIDEX Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Earnings Flash (IRIX) IRIDEX CORPORATION Posts Q1 Revenue $11.8M, vs. Street Est of $12M | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.83% | 42.1M | - | ||
+11.31% | 226B | B | ||
+15.50% | 198B | B- | ||
+18.83% | 142B | B- | ||
+30.38% | 111B | A- | ||
+2.59% | 65.26B | A- | ||
+18.31% | 54.36B | B+ | ||
+4.96% | 50.94B | B+ | ||
+9.95% | 44.8B | A | ||
+4.27% | 36.8B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- IRIX Stock
- Ratings IRIDEX Corporation